Objectives

• Define PNH
• Describe the serious morbities and mortality in patients with PNH
• Describe the appropriate high-risk patient populations and testing methods for PNH
• Define the nurse’s role in the assessment and management of patients with PNH

Please join us for this unique educational opportunity in one of these locations:

No continuing nursing education (CNE) contact hours will be awarded. When registering for this program, you will acknowledge that it does not offer CNE.

ONS:Edge, Inc., a subsidiary of the Oncology Nursing Society (ONS), is hosting this educational event, supported by Alexion Pharmaceuticals, Inc. The Oncology Nursing Society does not endorse or assume any responsibility for the educational content of this event.

By accepting any food and/or refreshments at this program, you certify that neither your employer nor the particular state(s) in which you are licensed impose restrictions that preclude you from accepting these items.

Specifically, the panelists will discuss:

• Strategies and Best Practices for Identifying NP/PA Thought Leaders
• NP Roles in Patient Education and Product Education
• Leveraging NP/PA Feedback for Educational Materials, including Ad Boards and Speaker Programs
• Current Opportunities to Incorporate NP/PA Knowledge into Business Planning

Download today!

Help your patients cope with the effects of Neuropathy.

• Discuss the factors associated with risk of severe neutropenia and life-threatening infection in patients with cancer who are treated with chemotherapy
• Review common sites of infection and common pathogens
• Explain sepsis and other infectious complications, as well the incidence of sepsis and septic death among patients with cancer
• Identify patients who are at increased risk of serious complications
• Describe the role of appropriate antibiotic therapy in the treatment of patients experiencing FN
• Inform oncology nurses about how they should:
  • Evaluate patients with signs and symptoms of infection
  • Educate patients with cancer who are treated with chemotherapy about helping to reduce the risk of infection

These are just some of the points that will be addressed at this nurse speaker dinner program that is being presented at the following locations:

No continuing nursing education (CNE) contact hours will be awarded.

• XGEVA is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors

• XGEVA is not indicated for the prevention of skeletal-related events in patients with multiple myeloma

Important Safety Information:

• Hypocalcemia: XGEVA can cause severe hypocalcemia. Correct pre-existing hypocalcemia prior to XGEVA treatment. Monitor calcium levels and administer calcium, magnesium, and vitamin D as necessary. Monitor levels more frequently when XGEVA is administered with other drugs that can also lower calcium levels. Advise patients to contact a healthcare professional for symptoms of hypocalcemia.

  Based on clinical trials using a lower dose of denosumab, patients with a creatinine clearance less than 30 mL/min or receiving dialysis are at greater risk of severe hypocalcemia compared to patients with normal renal function. The risk of hypocalcemia at the recommended dosing schedule of 120 mg every 4 weeks has not been evaluated in patients with a creatinine clearance less than 30 mL/min or receiving dialysis.

• Osteonecrosis of the Jaw (ONJ): Osteonecrosis of the jaw (ONJ) can occur in patients receiving XGEVA (denosumab), manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery may also be manifestations of ONJ.

  Perform an oral examination and appropriate preventive dentistry prior to the initiation of XGEVA and periodically during XGEVA therapy. Advise patients regarding oral hygiene practices. Avoid invasive dental procedures during treatment with XGEVA.

  Patients who are suspected of having or who develop ONJ while on XGEVA should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

• Adverse Reactions: The most common adverse reactions in patients receiving XGEVA (denosumab) were fatigue/asthenia, hypophosphatemia, and nausea.

  The most common serious adverse reaction in patients receiving XGEVA was dyspnea.

  The most common adverse reactions resulting in discontinuation of XGEVA were osteonecrosis and hypocalcemia.

Please see accompanying Prescribing Information

In adherence with PhRMA guidelines, this program is for healthcare professionals only.

Inclusion of a healthcare professional’s spouse or other guest is not appropriate.

Healthcare Practitioners and Providers licensed in Massachusetts, Vermont, and Minnesota: to comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Massachusetts, Vermont, and Minnesota, and (2) individuals employed by prescribers in Massachusetts and Vermont who support the provision of healthcare. We appreciate your understanding and support.

Amgen and ONS:Edge invite you to a dinner and discussion about XGEVA^® for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.

Program Objectives:

• Discuss the oncology nurse’s role
• Describe the serious and clinically significant consequences of SREs
• Examine the role of XGEVA for the prevention of SREs
• Review XGEVA safety data

Join us!
Register to ensure your seat.

Note: By providing your email and fax, you are granting permission to ONS:Edge and Amgen to communicate with you via fax or email. ONS:Edge and Amgen will not share email or fax information with outside entities.

No continuing nursing education (CNE) contact hours will be awarded.

This program has been planned by ONS:Edge, Inc., a subsidiary of the Oncology Nursing Society, and developed and supported by Amgen.

Anemia is a common struggle for patients with cancer. 40%-60% of patients receiving chemotherapy experience the disease state, across many types of cancer and various chemotherapies.¹

Amgen and ONS:Edge have collaborated on a yearlong initiative to educate on the recognition and assessment of anemia, particularly in oncologic settings. Please join us for a dinner event that will help oncology nurses

• Understand the effect of cancer and/or chemotherapy on erythropoiesis and the resulting anemia that often develops.
• Elevate awareness of the signs and symptoms of anemia in patients with cancer.
• Appreciate impact and health consequences of anemia on the management of patients with cancer.
• Develop the ability to discuss anemia and educate patients with cancer about anemia.
• Understand and apply proactive management of anemia to improve patient functional status.

At the event, noted members of the Oncology Nursing Society will discuss how red blood cells are produced, how that process can be affected in patients with cancer and those receiving chemotherapy, how healthcare providers can define and diagnose anemia, how the disease state may affect patients, and the critical role of nurses in identifying and assessing anemia. Attendees will have an opportunity to take educational materials back to their practices.

Please join us for this unique educational opportunity.

Register Now

No continuing nursing education (CNE) contact hours will be awarded. When registering for this program,
you will acknowledge that it does not offer CNE.

This program has been planned and developed in collaboration by Amgen Inc. and ONS:Edge, Inc., a subsidiary of ONS, and is sponsored by Amgen Inc.

Healthcare practitioners and providers licensed in Massachusetts, Vermont, or Minnesota: To comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Massachusetts, Vermont, or Minnesota; and (2) individuals employed by prescribers in Massachusetts or Vermont who support the provision of health care. We appreciate your understanding and support.

Note. By providing your e-mail address, you are granting permission to ONS, its subsidiaries, and Amgen Inc. to communicate with you via e-mail. ONS and its affiliates will not share e-mail information with outside entities.

1. Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009;31:2416-2432.

According to a randomly selected, blinded U.S. national survey conducted by Bard Access Systems, Inc., 93% of responding oncology nurses surveyed ranked ports as their chemotherapy delivery method of choice.

The VEINS FOR LIFE* awareness program was created to help you and other oncology clinicians:

• Understand the advantages and disadvantages of ports and other I.V. chemotherapy delivery options
• Educate patients on how ports work and how they may help to positively impact a patient’s lifestyle and comfort
• Hear from patients who share their experiences on how an implanted port has helped them in their therapy

Matching the Appropriate Access Device to Patients’ Treatment Needs

To help you decide on whether an implanted port or another vascular access device is right for your chemotherapy patients—and assist you in educating patients about available chemotherapy delivery options—visit www.VEINS4LIFE.com. A port can take your patient from the beginning to the end of treatment.

According to a randomly selected, blinded U.S. national survey conducted by Bard Access Systems, Inc., 93% of responding oncology nurses surveyed ranked ports as their chemotherapy delivery method of choice.

The VEINS FOR LIFE* awareness program was created to help you and other oncology clinicians:

• Understand the advantages and disadvantages of ports and other I.V. chemotherapy delivery options
• Educate patients on how ports work and how they may help to positively impact a patient’s lifestyle and comfort
• Hear from patients who share their experiences on how an implanted port has helped them in their therapy

Matching the Appropriate Access Device to Patients’ Treatment Needs

To help you decide on whether an implanted port or another vascular access device is right for your chemotherapy patients—and assist you in educating patients about available chemotherapy delivery options—visit www.VEINS4LIFE.com. A port can take your patient from the beginning to the end of treatment.

Baseline Assessment: This assessment is intended to be used prior to treatment to evaluate the likelihood that a patient may develop mucositis during therapy.

Periodic Assessment: This tool is intended to assess a patient’s changing symptoms during therapy.